Saiba Animal Health:
A new class of effective & affordable medicine for pets
Saiba Animal Health has developed a novel and innovative vaccine platform that is based on non-infectious virus-like particles in order to treat chronic inflammatory diseases, cancer and allergy in pets.
Latest
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
Innovation
Saiba Animal Health’s patented vaccine technology transforms the most recent and effective class of human medicines into a new, effective and affordable class of veterinary medicine.
Our vaccines instruct the pet’s immune system to make target-specific antibodies, which can inhibit any disease-promoting or disease-associated molecules.
Technology
Our team of innovative scientists, veterinarians and businessmen has pioneered and developed expertise and proprietary rights relating to a unique virus-like particle (VLP) vaccine nanotechnology platform.
Saiba Animal Health’s VLP vaccines induce strong, long-lived and highly specific, antibody responses against the disease target, which can inhibit disease-promoting or disease-associated self-proteins.
Pipeline
Saiba Animal Health has established a high-quality pipeline filled with promising new animal drug candidates that address major unmet needs in veterinary medicine.
Our scientists and network of scientific and veterinary collaborators contribute to our target selection and development focus.
Investors
Saiba Animal Health was founded as a spin-off company from the University Zurich in 2013.
SAH is looking to raise capital to fund ongoing and new R & D activities and form strategic alliances with top-tier companies to advance its pipeline projects and maximize the potential of its platform technology.